GlassScriptPhysician profile
Kristy Bestgen
NPI 1326487315
$4,389.51
in general payments reported to CMS, 2019-2025
32 companies · $1,411 in 2025
The $1,411 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $222 · 2022: $573 · 2023: $868 · 2024: $1,315 · 2025: $1,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,594.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $654.94 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $611.56 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $600.96 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $519.98 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $272.33 | 2021-2025 | Evenity, Otezla, Repatha |
| Pfizer INC. | $251.56 | 2021-2025 | |
| Glaxosmithkline, LLC. | $122.04 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $116.17 | 2023-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $103.12 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $98.12 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $88.75 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.26 | 2022-2025 | Trintellix |
| Esperion Therapeutics, INC. | $80.04 | 2024-2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.88 | 2021-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $72.66 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.77 | 2024-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $68.58 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.19 | 2021-2025 | Jardiance |
| Axsome Therapeutics, INC. | $57.30 | 2023-2024 | Auvelity |
| Tris Pharma INC | $52.85 | 2024-2025 | Dyanavel Xr |
| Kowa Pharmaceuticals America, INC. | $49.23 | 2021-2022 | |
| Corium, LLC | $48.24 | 2023 | Azstarys |
| Astellas Pharma US INC | $38.31 | 2023-2024 | Veozah |
| Abbott Laboratories | $30.58 | 2022-2023 | Freestyle Libre 3 |
| Dexcom, INC. | $30.44 | 2022-2024 | Dexcom G6 Transmitter |
| Nevro Corp. | $27.84 | 2024 | Senza |
| Exact Sciences Corporation | $19.59 | 2025 | Cologuard Collection Kit |
| Genentech USA, INC. | $17.84 | 2021 | |
| Phathom Pharmaceuticals, INC. | $15.25 | 2024 | Voquezna |
| Globus Medical, INC. | $15.00 | 2025 | Senza |
| Currax Pharmaceuticals LLC | $14.16 | 2023 | Contrave |
| Merck Sharp & Dohme LLC | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristy Bestgen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.